A venture capital firm founded in 2016 and with offices in the West Coast is actively investing in Seed to Series A rounds. In addition to providing equity capital, the firm will also assist companies with intellectual property. The firm is open to opportunities in North America (USA and Canada).

The firm is interested in early-stage medical technology, diagnostics, and digital health/wellness companies and is open to medical devices of all regulatory pathways including 510k and PMA. The firm strongly prefers products that have received FDA clearance but is open to working with pre-FDA products. The firm will generally not pursue opportunities in biopharma therapeutics.

The firm seeks to work with privately owned companies that are backed by an experienced management team. The firm likes to form syndicates and prefers co-investing in financing rounds, but the firm can lead rounds as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm founded in 2016 focused on cross-border investments. When investing, the firm doesn’t only provide financial capital, they also provide their global consulting services focused specifically on helping companies work across borders and in China. Currently, the firm is partnered with the Chinese Government to bring promising projects from North America to China and are focused on technologies that are at an advanced stage with patents that are willing to launch in Chinese markets or to set up factories and labs in China. The firm is however, willing to invest smaller amounts in good opportunities that have no interest/fit for the Chinese markets as well. The firm’s major focus within the life sciences is biotech and is focused on seed to series B rounds. The firm generally invests up to $10M USD for Series A deals, is flexible for series B rounds, and invests up to $1M USD for seed stage rounds.

Within the Life Sciences space, the firm is specifically focused on clinical tests, therapeutics, and other biotech technologies. The firm is also interested in medical devices focusing on large disease areas within China such as diabetes and cancer. Additionally, the firm is focused on technologies within these sectors that have a good fit with the Chinese Market or have a strong interest in working in China.

When investing, the firm looks to take a board seat. The firm provides consulting, localization services, and the ability to leverage resources in China to help the company grow alongside their direct equity investment and believe that these abilities can be best leveraged with a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the USA manages 5 funds for with its most recently fund having had its first close in 2017. The firm looks to provide up to $3-4 million of preferred equity capital in the initial round and up to $6 million over the life of the investment. The firm is very flexible in terms of period to exit but generally looks to exit in around 5 years. The firm will consider companies globally.

The firm is currently looking for companies developing Therapeutics and Medical Technology. Within therapeutics which is the firms primary focus, companies with an asset anywhere from preclinical with positive animal data to Phase II will be considered. The firm is generally open to all technology types and indications with the exception of wound care and psychiatry. Within devices, the firm is currently looking for market approved product with early revenue; however, devices are not an investment priority at present. The firm is looking for companies targeting true un-met medical needs where either no treatment currently exists or the existing standard of care is wrought with side-effects and other impediments to quality care.

The firm does not have any specific requirement for a firm’s management team although they are an active investor looking to take a seat on the company’s board. The firm -generally tends to lead or co-lead investments into selected companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A pharmaceutical company based in Seoul with annual sales of about $140 million with more than 600 employees has several clinical pipelines under global phase II in the area of CNS and diabetes, CNS clinical pipeline under phase III in Korea, and a late preclinical stage oncology product as well as an early preclinical candidates targeting TEC kinase family developed in-house.

The firm’s current marketing portfolio are mostly made of branded products licensed in from overseas partners. The firm is actively searching for innovative candidates and products around the world to incorporate into its pipeline and product portfolio. The firm has ample experience across various types of partnerships with overseas companies and is flexible in terms of the business structure. The firm is interested globally, including world-wide major territories.

The firm is currently seeking promising novel therapeutic candidates to incorporate into its pipeline. In terms of indications, the firm is indication agnostic with added interest in movement disorders, CNS, liver disease and immunology. The firm is also interested in oncology indications (small molecule or biologics with novel MoA). The firm prefers assets both in early/late non-clinical development stage as well as in early clinical development stage. The firm is also interested in obtaining distribution rights for innovative treatment in Phase III or in marketing authorization process.

The firm is open to working with companies anywhere in the world, and has no set requirements for partners; the firm is able to work with virtual drug companies by leveraging the firm’s own capabilities and third party relationships.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm that operates through several offices in USA and Asia manages over $750 million in committed capital across 8 funds. The most recent fund closed at $175M, and the firm focuses on early stage companies in Technology and Healthcare sectors with an initial investment size ranging from $500k to $5M. The firm primarily looks to invest in companies based in USA and China.

The firm is currently looking for new investment opportunities in Diagnostics, Medical Devices, Digital Health and Advanced Materials sectors. The firm is very opportunistic in terms of subsectors and indications, and is open to all classes of devices. The firm prefers to invest companies in pre-clinical and clinical stage, but it is open to consider companies with products on the market. Historically, the firm was active in companies developing diagnostic services and instrumentation, fetal monitoring and ultrasound systems, a stem cell bank, numerous health IT and vascular closure devices.

The firm invests in both private and public companies with a strong management team. The firm doesn’t have specific requirements for companies’ revenue or EBITDA. The firm looks to take a Board seat post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture/life science investment arm of an Asia-based life science, and medical equipment manufacturer invests from an evergreen fund and prefers to invest at company formation/seed stage, but no later than Series A. Typical investments range from $1-5M, but the fund will make larger tranched investments in case of therapeutic opportunities. The firm invests in companies worldwide. The firm can act as either a lead or a co-investor role. The firm prefers to invest at company formation or seed stages, with the latest stage they will invest being Series A.

The firm has four current focus areas: women’s health/fertility, life sciences tools & diagnostics, biotech (novel therapeutics), and PMA medical devices. The firm is interested broadly across all indications within these areas.

The firm prefers to invest in teams with a strong track record but has also worked with first-time entrepreneurs. The firm may or may not take a board seat in a portfolio company. If a company is seeking to expand into Asia, the firm can leverage the capabilities of the corporate to help companies with regulatory affairs, market access, and distribution, especially in the life sciences tools and fertility markets.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm founded in the 1990s with about 2 billion RMB in assets under management is currently investing out of their $30 million USD fund. Besides the $30M US dollar fund, the firm already has about $20M anchor secured and aim to raise around $70M for the 2nd dollar fund. The firm also shifted their paradigm that in the next 5 years, they will have 60% of the fund and portfolio companies from the USA. The firm focuses on Series A-B deals within the USA, Canada, and China and typically invests $2-5M per deal. The firm typically co-invests, but is willing to lead in specific situations.

The firm is opportunistic within the therapeutics and medical technology domains. However, for therapeutics, the firm focuses mostly on assets that are currently in Phase I or Phase II clinical trials. For Medical Devices, they prefer technologies that already have 510k or PMA clearance. Most importantly though, when investing, the firm requires that the technology has strong clinical evidence of efficacy. Strong evidence of efficacy is the most important criteria for the firm when investing in therapeutics and medical technology.

The firm is looking for a management team with a strong history of success as serial entrepreneurs or with strong clinical backgrounds. For investment opportunities without FDA clearance, the firm prefers seeing management teams with prior success in achieving FDA approval or candidates who have strong background from big pharma.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.